Cargando…

Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function

Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by pyrrolizidine alkaloids(PAs)-containing herbals. In this study, the aim of our study was to investigate the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced magnetic resonance imaging (MRI), susceptibility-weighted imagin...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Tingting, Li, Xin, Yang, Xiaoqian, Kong, Xiangquan, Liu, Hui, Bai, Tao, Xu, Keshu, Ye, Jin, Song, Yuhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362127/
https://www.ncbi.nlm.nih.gov/pubmed/30718698
http://dx.doi.org/10.1038/s41598-018-37775-1
_version_ 1783392836137254912
author Guo, Tingting
Li, Xin
Yang, Xiaoqian
Kong, Xiangquan
Liu, Hui
Bai, Tao
Xu, Keshu
Ye, Jin
Song, Yuhu
author_facet Guo, Tingting
Li, Xin
Yang, Xiaoqian
Kong, Xiangquan
Liu, Hui
Bai, Tao
Xu, Keshu
Ye, Jin
Song, Yuhu
author_sort Guo, Tingting
collection PubMed
description Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by pyrrolizidine alkaloids(PAs)-containing herbals. In this study, the aim of our study was to investigate the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced magnetic resonance imaging (MRI), susceptibility-weighted imaging(SWI) and T2* weighted imaging (T2* WI). We analyzed medical records and MR images of 28 PAs-induced HSOS patients enrolled from Feb, 2013, to Apr, 2017. Abnormal liver function was observed in most of the PAs-induced HSOS patients. Heterogeneity of liver parenchyma in hepatobillary phase (HBP) of gadoxetic acid-enhanced MR scan was observed in 100% of the PAs-induced HSOS patients. Distributional patterns of heterogeneous hypointensity were multifocal distribution (mild) in 4 patients (14.29%), multifocal distribution (severe) in 15 cases (53.57%), and diffuse distribution in 9 patients (32.14%). Hypointense in SWI and T2*WI was observed in the patients of PAs-induced HSOS, and the distribution of hypointense in SWI and T2*WI was similar to that of portal-venous phase of MR scan. The severity of heterogeneous hypointensity scored by volume fraction in hepatobillary phase of gadoxetic acid-enhanced MRI was positively correlated with PT and INR, the severity of hypointensity in HBP was a risk factor of death events. In conclusion: Heterogenous hypointensity of liver parenchyma was an imaging sign of hepatobillary phase in gadoxetic acid-enhanced MRI; thus, it will provide evidences for the diagnosis of PA-induced HSOS.
format Online
Article
Text
id pubmed-6362127
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63621272019-02-06 Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function Guo, Tingting Li, Xin Yang, Xiaoqian Kong, Xiangquan Liu, Hui Bai, Tao Xu, Keshu Ye, Jin Song, Yuhu Sci Rep Article Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by pyrrolizidine alkaloids(PAs)-containing herbals. In this study, the aim of our study was to investigate the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced magnetic resonance imaging (MRI), susceptibility-weighted imaging(SWI) and T2* weighted imaging (T2* WI). We analyzed medical records and MR images of 28 PAs-induced HSOS patients enrolled from Feb, 2013, to Apr, 2017. Abnormal liver function was observed in most of the PAs-induced HSOS patients. Heterogeneity of liver parenchyma in hepatobillary phase (HBP) of gadoxetic acid-enhanced MR scan was observed in 100% of the PAs-induced HSOS patients. Distributional patterns of heterogeneous hypointensity were multifocal distribution (mild) in 4 patients (14.29%), multifocal distribution (severe) in 15 cases (53.57%), and diffuse distribution in 9 patients (32.14%). Hypointense in SWI and T2*WI was observed in the patients of PAs-induced HSOS, and the distribution of hypointense in SWI and T2*WI was similar to that of portal-venous phase of MR scan. The severity of heterogeneous hypointensity scored by volume fraction in hepatobillary phase of gadoxetic acid-enhanced MRI was positively correlated with PT and INR, the severity of hypointensity in HBP was a risk factor of death events. In conclusion: Heterogenous hypointensity of liver parenchyma was an imaging sign of hepatobillary phase in gadoxetic acid-enhanced MRI; thus, it will provide evidences for the diagnosis of PA-induced HSOS. Nature Publishing Group UK 2019-02-04 /pmc/articles/PMC6362127/ /pubmed/30718698 http://dx.doi.org/10.1038/s41598-018-37775-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Guo, Tingting
Li, Xin
Yang, Xiaoqian
Kong, Xiangquan
Liu, Hui
Bai, Tao
Xu, Keshu
Ye, Jin
Song, Yuhu
Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title_full Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title_fullStr Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title_full_unstemmed Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title_short Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function
title_sort gadoxetic acid-enhanced hepatobiliary-phase magnetic resonance imaging for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome and association with liver function
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362127/
https://www.ncbi.nlm.nih.gov/pubmed/30718698
http://dx.doi.org/10.1038/s41598-018-37775-1
work_keys_str_mv AT guotingting gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT lixin gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT yangxiaoqian gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT kongxiangquan gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT liuhui gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT baitao gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT xukeshu gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT yejin gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction
AT songyuhu gadoxeticacidenhancedhepatobiliaryphasemagneticresonanceimagingforpyrrolizidinealkaloidinducedhepaticsinusoidalobstructionsyndromeandassociationwithliverfunction